Exhibit 99.1
(ADAMS RESPIRATORY LOGO)
     
 
  4 Mill Ridge Lane
 
  Mill Ridge Farm
 
  Chester, NJ 07930
 
  Main: 908-879-1400
 
  Fax: 908-879-9191
 
  www.adamsrt.com
ADAMS RESPIRATORY THERAPEUTICS REPORTS
FISCAL 2007 THIRD QUARTER FINANCIAL RESULTS
Solid year-over-year net sales growth driven by incremental sales of Delsym® and
Children’s Mucinex® and continued market penetration of Mucinex® DM
Highlights:
    Net sales of $84.0 million increased 11 percent.
 
    Retail consumption of Mucinex and Delsym products each increased more than 45 percent during the 2006-2007 cough/cold season in the cough/cold/allergy/sinus (C/C/A/S) category, according to Information Resources, Inc. (IRI) for the 28 weeks ended March 25, 2007.
 
    Adams’ dollar share of the total C/C/A/S category increased three market share points to 11.3 percent, for the 28 weeks ended March 25, 2007, versus prior year, according to IRI.
 
    Adams detailed the significant planned expansion and diversification of its product portfolio, including nine new OTC products, such as the Maximum Strength Mucinex and Mucinex Nasal Sprays product lines. (April)
 
    The New Drug Application, or NDA, for Mucinex with Codeine, a new prescription treatment for cough was accepted for filing by the FDA and is currently under regulatory review. (March)
 
    A settlement agreement was reached in the patent infringement lawsuit against Mutual Pharmaceutical. (March)
 
    An agreement was announced with MonoSol Rx, LLC that provides Adams access to oral thin-film drug delivery technology for future prescription and OTC products. (March)
CHESTER, N.J. (May 10, 2007) — Adams Respiratory Therapeutics, Inc. (NASDAQ: ARxT) today announced financial results for the fiscal third quarter ended March 31, 2007.
Commenting on the quarterly results, Michael J. Valentino, president and CEO said, “Overall, I am pleased with our solid top-line results and the in-season market performance of our brands. Our Mucinex and Delsym franchises both experienced the highest year-over-year sales growth of any brands in the cough/cold/allergy/sinus category, according to IRI for the 28 weeks ended March 25, 2007. We also exited the 2006-2007 cough/cold season with significant market share gains and increased consumer awareness. Additionally, we supported our key brands and newly launched products with effective consumer advertising and professional marketing support. All of these factors contributed to our exceptional performance in the competitive marketplace.”
Valentino added, “However, in spite of record retail consumption and strong market share gains for our brands this quarter, we believe our year-over-year growth in net sales was impacted primarily by

 


The following information was filed by Adams Respiratory Therapeutics, Inc. on Thursday, May 10, 2007 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Adams Respiratory Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adams Respiratory Therapeutics, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account